{"id":353,"date":"2014-04-22T09:50:23","date_gmt":"2014-04-22T07:50:23","guid":{"rendered":"https:\/\/mic-site.labiux.com\/uncategorized\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/"},"modified":"2026-10-06T06:29:26","modified_gmt":"2026-10-06T03:29:26","slug":"glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju","status":"publish","type":"post","link":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/","title":{"rendered":"&#8220;GlaxoSmithKline&#8221; un &#8220;Novartis&#8221; pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju"},"content":{"rendered":"<div class=\"wp-block-labiux-legacy-html legacy-content\">\n<p>Lielbrit\u0101nijas farm\u0101cijas uz\u0146\u0113mums &#8220;GlaxoSmithKline&#8221; un \u0160veices z\u0101\u013cu ra\u017eot\u0101js &#8220;Novartis&#8221; pazi\u0146oju\u0161i par savu vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju, kas paredz dar\u012bjumus vair\u0101ku miljardu dol\u0101ru apm\u0113r\u0101, zi\u0146o a\u0123ent\u016bra LETA.<\/p>\n<p>&#8220;GlaxoSmithKline&#8221; p\u0101rdos savu onkolo\u0123ijas biznesu &#8220;Novartis&#8221; par 16 miljardiem dol\u0101ru (11,5 miljardiem eiro) un ieg\u0101d\u0101sies \u0160veices uz\u0146\u0113muma vakc\u012bnu strukt\u016brvien\u012bbu par 7,05 miljardiem dol\u0101ru (5,08 miljardiem eiro).<\/p>\n<p>&#8220;GlaxoSmithKline&#8221; nor\u0101d\u012bjis, ka ien\u0101kumus no \u0161iem dar\u012bjumiem izmantos, lai akcion\u0101riem atgrieztu \u010detrus miljardus sterli\u0146u m\u0101rci\u0146u, zi\u0146o LETA.<\/p>\n<p>www.farmacija-mic.lv<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lielbrit\u0101nijas farm\u0101cijas uz\u0146\u0113mums &#8220;GlaxoSmithKline&#8221; un \u0160veices z\u0101\u013cu ra\u017eot\u0101js &#8220;Novartis&#8221; pazi\u0146oju\u0161i par savu vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju, kas paredz dar\u012bjumus vair\u0101ku miljardu dol\u0101ru apm\u0113r\u0101, zi\u0146o a\u0123ent\u016bra LETA. &#8220;GlaxoSmithKline&#8221; p\u0101rdos savu onkolo\u0123ijas [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11844,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"mic_cinema_image":0,"mic_focus":"","mic_cinema_focus":"","footnotes":"","_labiux_rail":0},"categories":[70,76],"tags":[],"mic_flag":[],"class_list":["post-353","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farmacijas-zinas","category-jaunakie-raksti"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.4 - aioseo.com -->\n\t<meta name=\"description\" content=\"Lielbrit\u0101nijas farm\u0101cijas uz\u0146\u0113mums &quot;GlaxoSmithKline&quot; un \u0160veices z\u0101\u013cu ra\u017eot\u0101js &quot;Novartis&quot; pazi\u0146oju\u0161i par savu vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju, kas paredz dar\u012bjumus vair\u0101ku miljardu dol\u0101ru apm\u0113r\u0101, zi\u0146o a\u0123ent\u016bra LETA.&quot;GlaxoSmithKline&quot; p\u0101rdos savu onkolo\u0123ijas biznesu &quot;Novartis&quot; par 16 miljardiem dol\u0101ru (11,5 miljardiem eiro) un ieg\u0101d\u0101sies \u0160veices uz\u0146\u0113muma vakc\u012bnu strukt\u016brvien\u012bbu par 7,05 miljardiem dol\u0101ru (5,08 miljardiem eiro).&quot;GlaxoSmithKline&quot; nor\u0101d\u012bjis, ka ien\u0101kumus no\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"admin\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.4\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"\u201cGlaxoSmithKline\u201d un \u201cNovartis\u201d pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:description\" content=\"Lielbrit\u0101nijas farm\u0101cijas uz\u0146\u0113mums &quot;GlaxoSmithKline&quot; un \u0160veices z\u0101\u013cu ra\u017eot\u0101js &quot;Novartis&quot; pazi\u0146oju\u0161i par savu vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju, kas paredz dar\u012bjumus vair\u0101ku miljardu dol\u0101ru apm\u0113r\u0101, zi\u0146o a\u0123ent\u016bra LETA.&quot;GlaxoSmithKline&quot; p\u0101rdos savu onkolo\u0123ijas biznesu &quot;Novartis&quot; par 16 miljardiem dol\u0101ru (11,5 miljardiem eiro) un ieg\u0101d\u0101sies \u0160veices uz\u0146\u0113muma vakc\u012bnu strukt\u016brvien\u012bbu par 7,05 miljardiem dol\u0101ru (5,08 miljardiem eiro).&quot;GlaxoSmithKline&quot; nor\u0101d\u012bjis, ka ien\u0101kumus no\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Glaxo-mazs.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Glaxo-mazs.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2014-04-22T07:50:23+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-10-06T03:29:26+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"\u201cGlaxoSmithKline\u201d un \u201cNovartis\u201d pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Lielbrit\u0101nijas farm\u0101cijas uz\u0146\u0113mums &quot;GlaxoSmithKline&quot; un \u0160veices z\u0101\u013cu ra\u017eot\u0101js &quot;Novartis&quot; pazi\u0146oju\u0161i par savu vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju, kas paredz dar\u012bjumus vair\u0101ku miljardu dol\u0101ru apm\u0113r\u0101, zi\u0146o a\u0123ent\u016bra LETA.&quot;GlaxoSmithKline&quot; p\u0101rdos savu onkolo\u0123ijas biznesu &quot;Novartis&quot; par 16 miljardiem dol\u0101ru (11,5 miljardiem eiro) un ieg\u0101d\u0101sies \u0160veices uz\u0146\u0113muma vakc\u012bnu strukt\u016brvien\u012bbu par 7,05 miljardiem dol\u0101ru (5,08 miljardiem eiro).&quot;GlaxoSmithKline&quot; nor\u0101d\u012bjis, ka ien\u0101kumus no\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Glaxo-mazs.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/farmacijas-zinas\\\/#listItem\",\"name\":\"Farm\\u0101cija\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/farmacijas-zinas\\\/#listItem\",\"position\":2,\"name\":\"Farm\\u0101cija\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/farmacijas-zinas\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#listItem\",\"name\":\"&#8220;GlaxoSmithKline&#8221; un &#8220;Novartis&#8221; pazi\\u0146o par vesel\\u012bbas apr\\u016bpes strukt\\u016brvien\\u012bbu reorganiz\\u0101ciju\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#listItem\",\"position\":3,\"name\":\"&#8220;GlaxoSmithKline&#8221; un &#8220;Novartis&#8221; pazi\\u0146o par vesel\\u012bbas apr\\u016bpes strukt\\u016brvien\\u012bbu reorganiz\\u0101ciju\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/farmacijas-zinas\\\/#listItem\",\"name\":\"Farm\\u0101cija\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#newsarticle\",\"name\":\"\\u201cGlaxoSmithKline\\u201d un \\u201cNovartis\\u201d pazi\\u0146o par vesel\\u012bbas apr\\u016bpes strukt\\u016brvien\\u012bbu reorganiz\\u0101ciju - Medikamentu Inform\\u0101cijas Centrs\",\"headline\":\"&#8220;GlaxoSmithKline&#8221; un &#8220;Novartis&#8221; pazi\\u0146o par vesel\\u012bbas apr\\u016bpes strukt\\u016brvien\\u012bbu reorganiz\\u0101ciju\",\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/Glaxo-mazs.png\",\"width\":400,\"height\":300},\"datePublished\":\"2014-04-22T09:50:23+03:00\",\"dateModified\":\"2026-10-06T06:29:26+03:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#webpage\"},\"articleSection\":\"Farm\\u0101cija, Jaun\\u0101kie raksti\",\"dateline\":\"Published on April 22, 2014.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"admin\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#webpage\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/\",\"name\":\"\\u201cGlaxoSmithKline\\u201d un \\u201cNovartis\\u201d pazi\\u0146o par vesel\\u012bbas apr\\u016bpes strukt\\u016brvien\\u012bbu reorganiz\\u0101ciju - Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Lielbrit\\u0101nijas farm\\u0101cijas uz\\u0146\\u0113mums \\\"GlaxoSmithKline\\\" un \\u0160veices z\\u0101\\u013cu ra\\u017eot\\u0101js \\\"Novartis\\\" pazi\\u0146oju\\u0161i par savu vesel\\u012bbas apr\\u016bpes strukt\\u016brvien\\u012bbu reorganiz\\u0101ciju, kas paredz dar\\u012bjumus vair\\u0101ku miljardu dol\\u0101ru apm\\u0113r\\u0101, zi\\u0146o a\\u0123ent\\u016bra LETA.\\\"GlaxoSmithKline\\\" p\\u0101rdos savu onkolo\\u0123ijas biznesu \\\"Novartis\\\" par 16 miljardiem dol\\u0101ru (11,5 miljardiem eiro) un ieg\\u0101d\\u0101sies \\u0160veices uz\\u0146\\u0113muma vakc\\u012bnu strukt\\u016brvien\\u012bbu par 7,05 miljardiem dol\\u0101ru (5,08 miljardiem eiro).\\\"GlaxoSmithKline\\\" nor\\u0101d\\u012bjis, ka ien\\u0101kumus no\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/Glaxo-mazs.png\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#mainImage\",\"width\":400,\"height\":300},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\\\/#mainImage\"},\"datePublished\":\"2014-04-22T09:50:23+03:00\",\"dateModified\":\"2026-10-06T06:29:26+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"\u201cGlaxoSmithKline\u201d un \u201cNovartis\u201d pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju - Medikamentu Inform\u0101cijas Centrs","description":"Lielbrit\u0101nijas farm\u0101cijas uz\u0146\u0113mums \"GlaxoSmithKline\" un \u0160veices z\u0101\u013cu ra\u017eot\u0101js \"Novartis\" pazi\u0146oju\u0161i par savu vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju, kas paredz dar\u012bjumus vair\u0101ku miljardu dol\u0101ru apm\u0113r\u0101, zi\u0146o a\u0123ent\u016bra LETA.\"GlaxoSmithKline\" p\u0101rdos savu onkolo\u0123ijas biznesu \"Novartis\" par 16 miljardiem dol\u0101ru (11,5 miljardiem eiro) un ieg\u0101d\u0101sies \u0160veices uz\u0146\u0113muma vakc\u012bnu strukt\u016brvien\u012bbu par 7,05 miljardiem dol\u0101ru (5,08 miljardiem eiro).\"GlaxoSmithKline\" nor\u0101d\u012bjis, ka ien\u0101kumus no","canonical_url":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/farmacija-mic.lv\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/#listItem","name":"Farm\u0101cija"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/#listItem","position":2,"name":"Farm\u0101cija","item":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#listItem","name":"&#8220;GlaxoSmithKline&#8221; un &#8220;Novartis&#8221; pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju"},"previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#listItem","position":3,"name":"&#8220;GlaxoSmithKline&#8221; un &#8220;Novartis&#8221; pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju","previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/#listItem","name":"Farm\u0101cija"}}]},{"@type":"NewsArticle","@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#newsarticle","name":"\u201cGlaxoSmithKline\u201d un \u201cNovartis\u201d pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju - Medikamentu Inform\u0101cijas Centrs","headline":"&#8220;GlaxoSmithKline&#8221; un &#8220;Novartis&#8221; pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju","author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Glaxo-mazs.png","width":400,"height":300},"datePublished":"2014-04-22T09:50:23+03:00","dateModified":"2026-10-06T06:29:26+03:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#webpage"},"isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#webpage"},"articleSection":"Farm\u0101cija, Jaun\u0101kie raksti","dateline":"Published on April 22, 2014."},{"@type":"Organization","@id":"https:\/\/farmacija-mic.lv\/en\/#organization","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","url":"https:\/\/farmacija-mic.lv\/en\/"},{"@type":"Person","@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author","url":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/","name":"admin","image":{"@type":"ImageObject","@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g","width":96,"height":96,"caption":"admin"}},{"@type":"WebPage","@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#webpage","url":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/","name":"\u201cGlaxoSmithKline\u201d un \u201cNovartis\u201d pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju - Medikamentu Inform\u0101cijas Centrs","description":"Lielbrit\u0101nijas farm\u0101cijas uz\u0146\u0113mums \"GlaxoSmithKline\" un \u0160veices z\u0101\u013cu ra\u017eot\u0101js \"Novartis\" pazi\u0146oju\u0161i par savu vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju, kas paredz dar\u012bjumus vair\u0101ku miljardu dol\u0101ru apm\u0113r\u0101, zi\u0146o a\u0123ent\u016bra LETA.\"GlaxoSmithKline\" p\u0101rdos savu onkolo\u0123ijas biznesu \"Novartis\" par 16 miljardiem dol\u0101ru (11,5 miljardiem eiro) un ieg\u0101d\u0101sies \u0160veices uz\u0146\u0113muma vakc\u012bnu strukt\u016brvien\u012bbu par 7,05 miljardiem dol\u0101ru (5,08 miljardiem eiro).\"GlaxoSmithKline\" nor\u0101d\u012bjis, ka ien\u0101kumus no","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/#website"},"breadcrumb":{"@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#breadcrumblist"},"author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"creator":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Glaxo-mazs.png","@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#mainImage","width":400,"height":300},"primaryImageOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/#mainImage"},"datePublished":"2014-04-22T09:50:23+03:00","dateModified":"2026-10-06T06:29:26+03:00"},{"@type":"WebSite","@id":"https:\/\/farmacija-mic.lv\/en\/#website","url":"https:\/\/farmacija-mic.lv\/en\/","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","inLanguage":"en-US","publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Medikamentu Inform\u0101cijas Centrs","og:type":"article","og:title":"\u201cGlaxoSmithKline\u201d un \u201cNovartis\u201d pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju - Medikamentu Inform\u0101cijas Centrs","og:description":"Lielbrit\u0101nijas farm\u0101cijas uz\u0146\u0113mums &quot;GlaxoSmithKline&quot; un \u0160veices z\u0101\u013cu ra\u017eot\u0101js &quot;Novartis&quot; pazi\u0146oju\u0161i par savu vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju, kas paredz dar\u012bjumus vair\u0101ku miljardu dol\u0101ru apm\u0113r\u0101, zi\u0146o a\u0123ent\u016bra LETA.&quot;GlaxoSmithKline&quot; p\u0101rdos savu onkolo\u0123ijas biznesu &quot;Novartis&quot; par 16 miljardiem dol\u0101ru (11,5 miljardiem eiro) un ieg\u0101d\u0101sies \u0160veices uz\u0146\u0113muma vakc\u012bnu strukt\u016brvien\u012bbu par 7,05 miljardiem dol\u0101ru (5,08 miljardiem eiro).&quot;GlaxoSmithKline&quot; nor\u0101d\u012bjis, ka ien\u0101kumus no","og:url":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/","og:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Glaxo-mazs.png","og:image:secure_url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Glaxo-mazs.png","og:image:width":400,"og:image:height":300,"article:published_time":"2014-04-22T07:50:23+00:00","article:modified_time":"2026-10-06T03:29:26+00:00","twitter:card":"summary_large_image","twitter:title":"\u201cGlaxoSmithKline\u201d un \u201cNovartis\u201d pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju - Medikamentu Inform\u0101cijas Centrs","twitter:description":"Lielbrit\u0101nijas farm\u0101cijas uz\u0146\u0113mums &quot;GlaxoSmithKline&quot; un \u0160veices z\u0101\u013cu ra\u017eot\u0101js &quot;Novartis&quot; pazi\u0146oju\u0161i par savu vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju, kas paredz dar\u012bjumus vair\u0101ku miljardu dol\u0101ru apm\u0113r\u0101, zi\u0146o a\u0123ent\u016bra LETA.&quot;GlaxoSmithKline&quot; p\u0101rdos savu onkolo\u0123ijas biznesu &quot;Novartis&quot; par 16 miljardiem dol\u0101ru (11,5 miljardiem eiro) un ieg\u0101d\u0101sies \u0160veices uz\u0146\u0113muma vakc\u012bnu strukt\u016brvien\u012bbu par 7,05 miljardiem dol\u0101ru (5,08 miljardiem eiro).&quot;GlaxoSmithKline&quot; nor\u0101d\u012bjis, ka ien\u0101kumus no","twitter:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Glaxo-mazs.png"},"aioseo_meta_data":{"post_id":"353","title":null,"description":null,"keywords":null,"keyphrases":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"limit_modified_date":false,"ai":null,"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-09-23 01:05:53","updated":"2026-10-07 11:30:02"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/\" title=\"Farm\u0101cija\">Farm\u0101cija<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t\u201cGlaxoSmithKline\u201d un \u201cNovartis\u201d pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/farmacija-mic.lv\/en\/"},{"label":"Farm\u0101cija","link":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/"},{"label":"&#8220;GlaxoSmithKline&#8221; un &#8220;Novartis&#8221; pazi\u0146o par vesel\u012bbas apr\u016bpes strukt\u016brvien\u012bbu reorganiz\u0101ciju","link":"https:\/\/farmacija-mic.lv\/en\/glaxosmithkline-un-novartis-pazino-par-veselibas-aprupes-strukturvienibu-reorganizaciju\/"}],"_links":{"self":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/comments?post=353"}],"version-history":[{"count":1,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/353\/revisions"}],"predecessor-version":[{"id":2084,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/353\/revisions\/2084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media\/11844"}],"wp:attachment":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media?parent=353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/categories?post=353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/tags?post=353"},{"taxonomy":"mic_flag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/mic_flag?post=353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}